Hitachi Chemical to Acquire apceth Biopharma to Expand Cell/Gene Therapy Contract Development.

M2 EQUITYBITES-February 1, 2019-Hitachi Chemical to Acquire apceth Biopharma to Expand Cell/Gene Therapy Contract Development

(C)2019 M2 COMMUNICATIONS http://www.m2.com

1 February 2019 - New Jersey, US-based Hitachi Chemical Advanced Therapeutics Solutions, LLC has agreed to acquire Germany based apceth Biopharma GmbH, a contract manufacturer of cell and gene therapy products, to strengthen presence in cell and gene therapy market, the company said.

Terms of the transaction were not disclosed. The closing of the transaction is planned for April 2019.

apceth will join Hitachi Chemical's PCT global services platform.

Through this deal, Hitachi Chemical will acquire two state-of-the-art GMP/BSL2 production facilities including 600 m2 of cleanroom area.

Hitachi Chemical Advanced Therapeutics Solutions, LLC (HCATS), is a wholly owned subsidiary of Hitachi Chemical company, Ltd. (Hitachi Chemical) representing Hitachi Chemical's Regenerative Medicine Business Sector in the United States. HCATS leverages nearly two decades of experience exclusively focused on the cell therapy industry.

apceth Biopharma manufactures cell and gene therapy products for American and European clients through two manufacturing sites in Munich, Germany.

((Comments on this story may be sent to [email protected]))